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Melanoma is the most aggressive skin cancer once
metastasis begins; therefore, it is important to char-
acterize the molecular players involved in melanoma
dissemination. The chemokine receptor CXCR4 and
the membrane-bound metalloproteinase MT1-MMP
are expressed on melanoma cells and represent can-
didate molecules for the control of metastasis. Using
human melanoma transfectants that either overex-
press or silence CXCR4 or MT1-MMP, or that have a
combination of overexpression and interference of
these proteins, we show that CXCR4 and MT1-MMP
coordinate their activities at different steps along
melanoma cell metastasis into the lungs. Results
from in vivo xenograft mouse models of melanoma
lung colonization and mice survival and short-
term, homing nested polymerase chain reaction
experiments from lung samples indicated that
CXCR4 is required at early phases of melanoma cell
arrival in the lungs. In contrast , MT1-MMP is not
needed for these initial steps but promotes subse-
quent invasion and dissemination of the tumor with
CXCR4. Investigation of potential cross talk be-
tween CXCR4 and MT1-MMP revealed that MT1-MMP
accumulates intracellularly after melanoma cell stim-
ulation with the CXCR4 ligand CXCL12, and that this
process involves the activation of the Rac-Erk1/2
pathway. Subsequent to cell contact with specific
basement membrane proteins, MT1-MMP redistrib-
utes to the cell membrane in a phosphatidylinositol
3-kinase-dependent manner. These results suggest
that combination therapies that target CXCR4 and
MT1-MMP should improve the limitations of the cur-
rent therapies for metastatic melanoma.
Trafficking of cancer cells from primary tumor sites via
intravasation into blood circulation and later extravasa-
tion to colonize distant organs requires tightly regulated
directional cues and cell migration and extracellular ma-
trix (ECM) degradation that are mediated by chemokines,
growth factors, integrins, and metalloproteinases.1 Solid
tumor cells express chemokine receptors that provide
guidance to these cells to organs where their ligands are
expressed, constituting a homing model resembling the
one used by immune cells to exert their immune surveil-
lance functions.2
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CXCR4 is a chemokine receptor expressed by tumor
cells in melanoma, breast, prostate, and colon cancer.3–6
Its ligand CXCL12 (also called SDF-1) is expressed in
lymph nodes, lungs, bone marrow, and liver.3 The impor-
tance of the CXCR4/CXCL12 axis in cancer is exemplified
by the fact that blocking CXCR4 function leads to inhibi-
tion of metastasis in in vivo mouse models of breast car-
cinoma and pancreatic cancer.3,7,8
Melanoma incidence has been steadily growing in
western populations. Although melanoma only accounts
for less than 5% of skin cancers, current therapies are
primarily refractory for metastatic melanoma. Therefore,
melanoma is responsible for 80% of deaths from skin
cancers.9 Expression of CXCR4 in human melanoma has
been detected in the vertical growth phase and on re-
gional lymph nodes and correlated with poor prognosis
and increased mortality.10,11 We previously demonstrated
that CXCL12 stimulates in vitro melanoma cell invasion
involving Vav-Rho GTPase activation, as well as activa-
tion of the metalloproteinase MT1-MMP/MMP-2 ECM-de-
grading system.12,13
MT1-MMP is a key component of the pericellular pro-
teolysis machinery involved in degradation of gelatin,
laminin, and fibrillar collagens and is an activator of pro-
MMP-2 in coordination with TIMP-2.14,15 Accordingly, its
cell membrane expression must be tightly controlled to
avoid excessive ECM pericellular degradation. Further-
more, MT1-MMP proteolytic activity controls cell adhe-
sion and growth.14,15 MT1-MMP is expressed on mela-
noma, and breast and lung cancer, and its expression
often correlates with tumor invasiveness across tissue
barriers.16–19 MT1-MMP and MMP-2 are found in malig-
nant melanoma often associated to the invading tumor
front,20,21 suggesting that their proteolytic activity could
be involved in melanoma cell dissemination.
Whereas the above data support an important role for
CXCR4 and MT1-MMP in melanoma metastasis, the po-
tential functional relationships and mechanistic coordina-
tion of these molecules in lung metastasis, as well as their
roles at different steps of melanoma cell homing into
lungs, have not been evaluated. In the present study we
have generated stable transfectants of the highly meta-
static human melanoma cell line BLM expressing combi-
nations of overexpression and silencing of CXCR4 and
MT1-MMP to investigate whether these proteins establish
coordinated activities during in vivo melanoma metasta-
sis. The results reveal that CXCR4 and MT1-MMP need
each other’s activities during melanoma metastasis into
lungs and provide mechanistic characterization of mo-
lecular cross-talks between these proteins. The data sug-
gest that combinatorial therapies against these proteins
might provide beneficial advantages to inhibit melanoma
metastasis.
Materials and Methods
Cells, Antibodies, and Reagents
BLM human melanoma cells were cultured as previously
described.4 Anti-CXCR4 antibodies were from R&D Sys-
tems (Minneapolis, MN), anti-MT1-MMP LEM-2/15 mAb
was a gift from Dr. Alicia G. Arroyo (Centro Nacional de
Investigaciones Cardiovasculares, Madrid, Spain), and
control P3X63 and antibodies to 1 and 4 integrins (Lia
1/2.1 and HP1/2, respectively) were from Dr. Francisco
Sa´nchez-Madrid (Hospital de la Princesa, Madrid,
Spain). Anti-Rac1 antibodies were from BD Biosciences
(San Diego, CA), anti-RhoA from Santa Cruz Biotechnol-
ogy (Santa Cruz, CA), anti--actin from Sigma-Aldrich
(St. Louis, MO), anti-GFP from Molecular Probes (Eu-
gene, OR), and anti-Erk1/2, anti-phospho-Erk1/2, anti-
Akt, and anti-phospho-Akt (Ser473) antibodies were from
Cell Signaling Technology (Danvers, MA). Type IV colla-
gen and LY294002 were from Sigma-Aldrich Co., and
U0126 from Calbiochem (Darmstadt, Germany). We used
a laminin 1-rich extract from Sigma-Aldrich (catalog no.
L2020) as source for laminin. Transforming growth fac-
tor-1 and epidermal growth factor were obtained from
R&D Systems.
Vectors, siRNA, Transfections, and Retroviral
Gene Transfer
The pEGFP-C1 vector or GFP-fused forms of wild-type or
activated V12-Rac1 were gifts from Dr. Francisco
Sanchez-Madrid and were transfected into BLM cells
following the described method.13 siRNA for Rac1 has
been earlier reported22 and was transfected into BLM
cells according to the published procedure.13 CXCR4
and MT1-MMP shRNA vectors were based on 19-mer
sequences (5-GCAGTCCATGTCATCTACA-3, for CXCR4;
5-TTGGCAGCCTCTCACTACT-3, for MT1-MMP), which
constitute targets for siRNA-mediated interference.13
Synthetic oligonucleotides (64-mer) that include these
19-mer sequences were synthesized, annealed, and li-
gated into pSuper vector as described.23 pSuper cas-
settes coding CXCR4 or MT1-MMP shRNAs were cloned
into pRETRO-Hygro vector,24 generating pRETRO-Su-
per-CXCR4 and pRETRO-Super-MT1-MMP. cDNAs for
CXCR4 and MT1-MMP (from Dr. Jose´ Miguel Rodríguez-
Frade, Centro Nacional de Biotecnología, Madrid, Spain,
and Dr. Alicia G. Arroyo, respectively) were cloned into
pRetro-Blast retroviral vector24 for overexpression of
CXCR4 and MT1-MMP (pRetro-CXCR4 and pRetro-MT1-
MMP, respectively). Retroviral particles were obtained by
co-transfecting these vectors with plasmids coding for
retroviral proteins gag.pol (pNGVL-MLV-gag-pol)25 and
the vesicular stomatitis virus envelope glycoprotein
(pNGVL-VSV-G),26 into 293FT packaging cells using li-
pofectamine (Invitrogen Corp., Carlsbad, CA). Condi-
tioned media containing viral particles were used to
infect BLM cells, which were selected with blasticidin
(Invitrogen Corp.) or hygromicin (Calbiochem), obtain-
ing sublines with interference (CXCR4lo and MT1lo),
overexpression (CXCR4hi and MT1hi), or simultaneous over-
expression and interference of CXCR4 and MT1-MMP
(CXCR4hiMT1lo and CXCR4loMT1hi). As a control, we in-
fected BLM cells with empty pRETRO-containing viral
particles to generate the mock subline.
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Flow Cytometry, Western Blotting,
and Zymography
Melanoma cells were incubated with primary antibodies,
followed by incubation with fluorescein isothiocyanate-
conjugated secondary antibodies (DAKO A/S, Copenha-
gen, Denmark) and analysis in an Epics XL cytofluorom-
eter (Beckman Coulter, Fullerton, CA). P3X63 was used
as control primary antibody. For Western blotting, cell
lysates were resolved by sodium dodecyl sulfate-polyac-
rylamide gel electrophoresis and proteins transferred to
membranes that were incubated with primary antibodies,
followed by incubation with horseradish peroxidase-con-
jugated secondary antibodies. Proteins were visualized
using SuperSignal chemiluminescent substrate (Pierce,
Rockford, IL). For zymography we used the described
method.13 Briefly, cells were lysed in Laemmli buffer, and
samples resolved on sodium dodecyl sulfate-polyacryl-
amide gel electrophoresis gels embedded with 1 mg/ml
of fibrinogen (Calbiochem-Novabiochem Co., Darmstadt,
Germany). Gels were rinsed in 2.5% Triton X-100, fol-
lowed by incubation in 50 mmol/L Tris-HCl, pH 7.5, 10
mmol/L CaCl2, and 200 mmol/L NaCl. Gels were stained
with Coomassie Blue, and areas of gelatinolytic activity
were visualized as transparent bands.
Proliferation and Cell Cycle Assays
Cells (1.2  105) were cultured in Dulbecco’s modified
Eagle’s medium/fetal bovine serum 1% with or without
CXCL12 (R&D Systems) (200 ng/ml), and after detach-
ment, cells were counted in a Neubauer chamber. For
cell cycle assays, cells were pulsed with 5-bromode-
oxyuridine (BrdU) (Sigma-Aldrich Co) (15 mol/L for 1
hour) and cultured for different times. Thereafter, cells
were detached, fixed with 70% ethanol, permeabilized
with 0.5% Triton X-100 in 2 mol/L HCl, and washed with
0.1 mol/L sodium tetraborate. Finally, cells were incu-
bated with fluorescein isothiocyanate-conjugated anti-
BrdU antibodies (BD Biosciences), followed by analysis
in a cytofluorometer. Cell cycle time was estimated as the
interval necessary to have a ratio of BrdU-labeled cells in
S phase to BrdU-labeled cells in G2 phase equal as in 0
hours time.
Invasion and Adhesion Assays
Invasions across Matrigel were done as previously estab-
lished.12 Briefly, cells (3.5  104) were loaded on the
upper compartments of invasion chambers coated with
Matrigel (BD Biosciences, Bedford, MA). The lower com-
partments were filled with invasion medium with or with-
out CXCL12. Invasive cells were fixed, stained, and
counted under a microscope. For adhesion to Matrigel,
cells (6  105) were labeled for 20 minutes at 37°C with
2,7-bis(carboxyethyl)-5(6)-carboxyfluorescein-acetoxym-
ethyl ester (Molecular Probes), and after pre-incubation
with antibodies, cells in triplicates (3  104) were loaded
on 96-well dishes (Costar, Cambridge, MA) coated with
Matrigel (1 g/ml). Cells were allowed to adhere for 10
minutes at 37°C and, on washing to remove unbound
cells, adhesion was quantified using a fluorescence an-
alyzer (Polarstar Galaxy, Offenburg, Germany).
Animal Studies
BALB/c SCID mice (Harlan, Indianapolis, IN) bred and
maintained under specific pathogen-free conditions were
used for xenograft studies. The Consejo Superior de
Investigaciones Cientificas Ethics Committee (Madrid,
Spain) approved the protocols used for experiments with
mice. Mice were injected subcutaneously in the lateral
thoracic wall or intravenously into the tail vein with 2 
106 cells resuspended in 0.2 ml of phosphate-buffered
saline (PBS). Mice were daily inspected for local tumor
growth and general condition, and were sacrificed when
clear signs of respiratory stress were noted, or when
subcutaneous tumors reached volumes of 2.5 cm3. For
nested reverse transcriptase-polymerase chain reaction
(RT-PCR), portions of lungs from mice inoculated with
GFP-expressing melanoma transfectants were lysed in
Tri-Reagent (Sigma-Aldrich Co.), and RNA was extracted
and reverse-transcribed. PCR was performed using
TaqDNA polymerase (Invitrogen Corp.) and outer prim-
ers for GFP: 5-GACTGGGTGCTCAGGTAGTG-3 and
5-GTAAACGGCCACAAGTTCAG-3. A 1-l PCR product
was further amplified using inner primers for GFP: 5-TCGT-
GACCACCCTGACCTAC-3 and 5-TCACCTTGATGCCGT-
TCTTC-3. The first PCR profile was 35 cycles of 45-
second denaturation at 94°C, 45-second annealing at
52°C, and 1-minute polymerization at 72°C. The second
PCR was performed in the same way, except that only 30
cycles were performed and annealing was executed at
56°C. For positron emission tomography (PET) analyses,
mice were anesthetized with isoflurane, followed by ad-
ministration of [18F]-fluorodeoxyglucose (624  49 Ci)
via the tail vein before analyses. Mice were scanned in a
dedicated small animal PET scanner (rPET; Suinsa, Ma-
drid, Spain), and tomographic images reconstructed us-
ing a three-dimensional FBP algorithm creating 55 55 
55 images. Voxel size was 0.81  0.81  0.81 mm3, and
the spatial resolution was 1.65 mm full width at half max-
imum isotropic. The energy window was 400 to 700 keV,
and decay and dead-time corrections were applied. For
computed tomography (CT) studies, mice were scanned
using a CT scanner (HQT-Y15D, Suinsa) for small ani-
mals. CT acquisition was performed as follows: one bed
position, 200 A, 50 kV, 200 m pixel size, and 360
projections. PET and CT images were co-registered us-
ing a marker-based rigid registration algorithm to obtain
an initial realignment followed by a refinement step based
on a mutual information registration algorithm.
Statistical Analyses
Data were analyzed by one-way analysis of variance
followed by Tukey-Kramer multiple comparisons. In both
analyses, the minimum acceptable level of significance
was P  0.05.
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Results
In Vivo Melanoma Metastasis Requires CXCR4
and MT1-MMP Coordinated Activities
To investigate if functional coordination between CXCR4
and MT1-MMP is needed during melanoma cell metas-
tasis, we made BLM melanoma stable transfectants with
combined overexpression and silencing of these proteins
to be subsequently tested in in vivo models of metastasis.
To generate these transfectants, we used pRetro-Super
and pRetro retroviral vectors as templates for stably si-
lencing or for overexpression of CXCR4 and MT1-MMP,
respectively (see Materials and Methods). After antibiotic
selection, total transfectant populations were used for all
experiments without subsequent cloning. Flow cytometry
and Western blotting analyses of single CXCR4 or MT1-
MMP transfectants revealed that CXCR4lo and MT1lo
cells displayed minimal levels of CXCR4 and MT1-MMP
expression, whereas CXCR4hi and MT1hi transfectants
showed threefold and twofold higher expression of these
proteins than mock counterparts, respectively (Figure 1,
A and B). Accordingly, CXCR4hiMT1lo and CXCR4loMT1hi
double transfectants displayed overexpression and si-
lencing of CXCR4 or MT1-MMP.
To in vitro characterize the invasive properties of trans-
fectants, we subjected them to invasion assays across
Matrigel, a basement membrane matrix extract rich in
laminin, type IV collagen, heparan sulfate proteoglycans,
and growth factors, which constitutes a valuable in vitro
basis for assessing the invasive potential of tumor cells.27
CXCR4hi and MT1hi cells showed increased CXCL12-
promoted invasion compared with mock counterparts,
whereas CXCR4lo and MT1lo knockdown cells barely in-
vaded (Figure 1C). Interestingly, CXCR4hiMT1lo and
CXCR4loMT1hi transfectants displayed invasion levels
similar to single knockdown CXCR4lo and MT1lo cells,
suggesting that CXCR4 and MT1-MMP are mutually re-
quired for invasion of melanoma cells. In addition,
CXCR4hi and MT1hi transfectants displayed higher de-
gree of migration in wound-healing assays on Matrigel
layers in the presence of CXCL12 than CXCR4lo and
MT1lo counterparts (see Supplemental Figure S1A at
http://ajp.amjpathol.org), together indicating that in vitro
invasive and migratory properties of melanoma transfec-
tants reflect CXCR4 and MT1-MMP expression levels.
CXCR4hi transfectants displayed a modest growth ad-
vantage in medium containing CXCL12, compared with
CXCR4lo cells (Figure 1D). Cell cycle analyses with BrdU-
pulsed cells showed that high CXCR4 expression was
associated with shorter doubling times (22 hours) than
CXCR4 knockdown cells (26 hours), or mock transfec-
tants (24 hours) (Supplemental Figure S1B at http://ajp.
amjpathol.org). Instead, changes in MT1-MMP expres-
sion did not influence cell cycle kinetics.
To investigate if functional mutual requirement be-
tween CXCR4 and MT1-MMP observed in in vitro invasion
also takes place during in vivo metastasis, we first sub-
cutaneously injected the melanoma transfectants into
SCID mice and followed the growth and dissemination of
the tumors. MT1hi and CXCR4loMT1hi tumors grew signif-
icantly faster than MT1lo or CXCR4hiMT1lo ones (Figure
2A). Instead, silencing or overexpression of CXCR4 did
not affect the growth rate of melanoma cells, suggesting
that MT1-MMP, but not CXCR4, influences the growth of
subcutaneous melanoma tumors, in agreement with the
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Figure 1. In vitro functional characterization of human melanoma transfec-
tants with stable interference and overexpression of CXCR4 and MT1-MMP.
A: Flow cytometry analyses of CXCR4 and MT1-MMP expression on BLM
melanoma transfectants. Note the 3-decade log scale starting at 0 and ending
at 103. B: Western blotting analyses of CXCR4 and MT1-MMP expression on
BLM melanoma transfectants. Loading controls were assessed with anti-RhoA
antibodies. Shown is a representative result of three independent experi-
ments (top) and densitometer analyses in arbitrary units showing fold in-
duction of expression related to mock transfectants (bottom). C: Transfec-
tants were subjected to Matrigel invasion assays toward CXCL12 or medium
alone. Invasion was significantly up-regulated, *P  0.05, or significantly
inhibited, P  0.05, with respect to mock transfectant invasion. D: Trans-
fectants (1.2  105) were incubated in Dulbecco’s modified Eagle’s medi-
um/1% fetal bovine serum, without (medium) or with CXCL12, and cell
number was determined after the indicated times.
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reported MT1-MMP role in cell proliferation.19 None of the
mice injected with CXCR4lo or MT1lo transfectants had
invasive tumors. These tumors remained under the skin
without crossing into thoracic or abdominal cavities (not
shown), and no lung metastases were detected in these
mice (Figure 2B). In contrast, subcutaneously-injected
CXCR4hi and MT1hi melanoma cells reached the lungs
and formed metastatic nodes (one to two tumor nodes:
45% and 60% of mice, respectively). Importantly, metas-
tasis was impaired in CXCR4hiMT1lo and CXCR4loMT1hi
tumors (Figure 2B), indicating that silencing CXCR4 or
MT1-MMP reversed the invasive stimulation properties
provided by overexpression of the counterpart protein.
The pattern of CXCR4 and MT1-MMP expression and
CXCL12-promoted invasiveness across Matrigel of mel-
anoma cells derived from subcutaneous tumors or from
lung metastases was maintained with respect to the orig-
inally inoculated transfectants (see Supplemental Figure
S2, A and B, at http://ajp.amjpathol.org), confirming the
functional characteristics of both proteins along the met-
astatic process.
When melanoma transfectants were intravenously in-
oculated, we found that CXCR4lo and MT1lo mice dis-
played significantly longer survival than CXCR4hi and
MT1hi ones, respectively (Figure 3A). Lung examinations
revealed that 70 to 90% of CXCR4hi and MT1hi mice had
from five tumor nodes to widespread tumor dissemination
(Figure 3B). All CXCR4lo and MT1lo mice eventually de-
veloped lung metastasis, but only 10% had five or more
tumor nodes, indicating that high CXCR4 expression on
melanoma cells conferred strong lung invasiveness. No-
tably, CXCR4hiMT1lo and CXCR4loMT1hi mice showed a
substantially prolonged survival compared with CXCR4hi
and MT1hi counterparts, and high tumor node number or
massive lung metastases were only observed in 15 to
35% of mice inoculated with the double transfectants
(Figure 3B). Control experiments confirmed the expres-
sion of human GAPDH mRNA in addition to CXCR4 and
MT1-MMP in the lung tumor samples (see Supplemental
Figure S3 at http://ajp.amjpathol.org). These results indi-
cate that CXCR4 and MT1-MMP on melanoma establish
crucial coordinated activities for efficient lung
colonization.
The Role of CXCR4 and MT1-MMP in Early
Events of Melanoma Cell Homing into Lungs
To investigate CXCR4 and MT1-MMP involvement at ini-
tial migratory events during melanoma cell homing into
lungs, we first performed nested PCR using lung tissue
from mice intravenously inoculated with melanoma trans-
fectants that had been transiently transfected with
pEGFP-C1 as a reporter. Before PCR analyses, we veri-
fied by flow cytometry that all transfectants expressed
similar GFP levels (not shown). A GFP transcript in the
lungs of CXCR4hi mice was consistently detected in the
first round of nested PCR (outer primers) at 2 hours after
inoculation, which further increased on 24 hours of inoc-
ulation, whereas no GFP transcript was seen in CXCR4lo
or Mock mice at these times (Figure 3C). However, a GFP
product using the inners primers was evident at 2 hours
and 24 hours in lungs from CXCR4lo and Mock mice, in
addition of CXCR4hi counterparts. In contrast with
CXCR4, we did not observe significant differences in
nested PCR products from MT1hi and MT1lo mice after 24
hours of inoculation. Moreover, GFP transcript levels in
lungs from CXCR4hiMT1lo mice using the outer primers
were similar to those of CXCR4hi counterparts, and
CXCR4loMT1hi mice displayed only traces of GFP prod-
ucts in the first round of nested PCR. Together, these
data indicate that high CXCR4 expression provides
melanoma cells with greater homing efficiency during
early steps of lung colonization than CXCR4 knock-
down cells, and suggest that MT1-MMP does not play
relevant roles at these initial phases. Furthermore, we
found that the earlier accumulation of CXCR4hi mela-
noma cells in lungs led to a subsequent faster devel-
opment of metastases in this organ because a higher
frequency of CXCR4hi mice displayed tumors nodes
(one to two) that were detectable by PET-CT imaging
sooner than CXCR4lo mice (Figure 3D).
Firm attachment to endothelium is a required step for
posterior tumor cell invasion to form additional metastatic
sites.1 Immunohistochemistry analyses using antibodies
against HMW-MAA (also known as melanoma chondroitin
sulfate proteoglycan) revealed large clusters of mela-
noma cells around blood vessels in lungs from CXCR4hi
mice (see Supplemental Figure S4A at http://ajp.amjpathol.
org). In agreement with earlier results,28 we found that
high CXCR4 expression provided melanoma cells with
advantage to up-regulate their 41-dependent attach-
ment to VCAM-1 through CXCL12-promoted inside-out
signaling. Thus, in vitro adhesion assays under flow con-
ditions to VCAM-1 co-immobilized with CXCL12 revealed
that CXCR4hi cells had a fourfold higher resistance to
detachment than CXCR4lo or mock transfectants at shear
stresses up to 5 dyne/cm2 (see Supplemental Figure S4B
at http://ajp.amjpathol.org). Control experiments indicated
A
D
ay
st
o
de
ve
lo
p
tu
m
or
s≥
2.
5 
cm
3 
M
oc
k
M
T1
hi
CX
CR
4h
i
M
T1
lo
CX
CR
4l
o
CX
CR
4h
i M
T1
lo
CX
CR
4l
o M
T1
hi
20
30
40
50
10
0
N.S
.
p<0.001
N.S
.
N.S
.
B
CX
CR
4l
o M
T1
hi
M
T1
hi
CX
CR
4h
i
M
T1
lo
M
oc
k
20
40
60
80
0
Lung metastases
M
ic
e
(%
)
CX
CR
4l
o
CX
CR
4h
i M
T1
lo
p<0.01 p<0.05
Figure 2. Growth and lung metastasis of subcutaneously-inoculated CXCR4
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that pertussis toxin and anti-4 mAb abolished attach-
ment to VCAM-1 (not shown).
Erk1/2 MAP Kinase Regulates MT1-MMP
Expression, Whereas Phosphatidylinositol
3-Kinase Controls MT1-MMP Cell Surface
Redistribution
We previously showed that CXCL12 stimulates MT1-MMP
expression in melanoma cells at mRNA and protein lev-
els.12 However, enhancement in total cellular MT1-MMP
protein levels was not translated into increased cell
membrane protein expression on Mock and CXCR4hi
transfectants (Figure 4A, top and bottom), indicating a
predominant intracellular localization of this metallopro-
teinase on CXCL12 stimulation. As expected, no induc-
tion of MT1-MMP was detected in CXCR4lo transfectants.
To address whether intracellular MT1-MMP might redis-
tribute to the melanoma cell membrane after interaction
with basement membranes and endothelial ligands, we
analyzed its surface expression on CXCL12-stimulated
cells plated on Matrigel or other substrates. Notably,
nonstimulated transfectants displayed a significant in-
crease in cell membrane MT1-MMP expression on plat-
ing them on Matrigel for 45 minutes, compared with cells
incubated in invasion medium alone, and the increase
was of higher magnitude on CXCL12-stimulated CXCR4hi
and mock transfectants (Figure 4A, bottom). Correlating
with CXCR4 silencing, no further up-regulation of cell
membrane MT1-MMP levels was observed in CXCR4lo
transfectants pre-incubated with the chemokine. Kinetic
studies indicated that Matrigel-triggered increase in sur-
face MT1-MMP expression had a maximum at 45 min-
utes, and then gradually decreased with longer incuba-
tions (Figure 4B). Because laminin and type IV collagen
are main components of Matrigel, we tested their possi-
ble role in MT1-MMP redistribution to the melanoma cell
membrane. We found that incubation on laminin led to an
increase in cell surface MT1-MMP to levels similar to
those achieved with Matrigel, whereas plating on type IV
collagen did not induce such an effect (Figure 4C). In
addition, incubation with transforming growth factor-1 or
epidermal growth factor, which are also Matrigel constit-
B
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uents, or with VCAM-1, fibronectin, or gelatin, did not
influence melanoma cell MT1-MMP membrane levels
(Figure 4C; and see Supplemental Table S1 at http://
ajp.amjpathol.org). Control experiments indicated that 45-
minute incubation with Matrigel, VCAM-1, fibronectin, or
gelatin did not alter cell surface expression of CXCR4.
Stimulation by CXCL12 of total MT1-MMP expression
involved Erk1/2 MAP kinase activity because treatment
with the MEK inhibitor UO126 led to inhibition of increase
in the metalloproteinase expression, whereas the phos-
phatidylinositol 3-kinase (PI3-K) inhibitor LY294002 (LY)
did not affect the enhanced expression (Figure 5A), as
also earlier reported.13 Because activation of Vav1-Rac1
signaling by CXCL12 controls up-regulation of MT1-MMP
expression in melanoma,13 we next tested whether
Erk1/2 was a required Rac1 downstream target to in-
crease this expression. When BLM melanoma cells were
transfected with Rac1 siRNA, CXCL12-promoted en-
hancement in MT1-MMP expression was abrogated,
which was associated with blockade in the stimulation of
Erk1/2 phosphorylation (Figure 5B). Moreover, expres-
sion of a constitutively active Rac1 form (Rac CA) trig-
gered both an increase in MT1-MMP expression and in
Erk1/2 phosphorylation, compared with Rac wild-type
transfectants that were inhibited by UO126 (Figure 5C).
Notably, CXCL12-stimulated Rac CA transfectant inva-
sion was inhibited by UO126 and blocked by anti-MT1-
MMP mAb (Figure 5D, left). In addition, zymography as-
says showed that supernatants from Rac CA transfectant
invasions contained higher amounts of active MMP-2
than in Rac wild-type counterparts, whereas the pres-
ence of UO126 in the invasions resulted in inhibition of
pro-MMP-2 activation (Figure 5D, right). No MMP-9 was
detected in the invasion supernatants under our assay
CXCL12:
MT1-MMP
β-actin
- +     - +    - +
Mock CXCR4hi CXCR4lo
A
Mock CXCR4hi CXCR4lo
Matrigel
Medium
Medium
CXCL12
CXCL12
0 8 1 0 0 9
1 1 1 3 1 0
3 2 3 7 3 3
6 8 18 4 3 3
MT1-MMP expression
Control
Mean Fluorescence Intensity
100 101 1031020 100 101 103102 100 101 103102
Control
Laminin
Type IV 
Collagen
TGF-β1
EGF
1 1
3 1
1 4
1 1
1 1
Mean Fluorescence Intensity
100 101 1031020
MT1-MMP expression
C
0
1
2
3
0 45 90 180
Time with Matrigel
(min)
M
T
1-
M
M
P 
ex
pr
es
io
n
(M
FI
)  
 
B
Figure 4. MT1-MMP accumulates intracellularly
on CXCL12 stimulation and redistributes to the
cell surface after melanoma cell incubation with
basement membrane proteins. A: Melanoma
transfectants were incubated for 24 hours with
CXCL12 and subjected to immunoblotting with
anti-MT1-MMP mAb. Control loading was as-
sessed with -actin antibodies (top). Then cells
were plated for 45 minutes on Matrigel (1.5 g/
mm2) or incubated in invasion medium alone
(control), and after detachment with PBS/EDTA
they were analyzed for MT1-MMP cell surface
expression by flow cytometry (bottom). Mock
transfectants were plated for the indicated times
either on Matrigel (B), on the indicated ECM
proteins, or incubated with transforming growth
factor-1 or epidermal growth factor (C), and
subsequently analyzed by flow cytometry for
MT1-MMP cell surface expression. Note the
3-decade log scale starting at 0 and ending at 103.
Mock
CXCL12 : - +     - +      - +
Control LY UO126
MT1-MMP
β-actin
A
MT1-MMP
Phospho- 
Erk1/2
Total
Erk1/2
Rac1
Control Rac1
CXCL12:    - +         - +
B siRNA
Rac CA
UO126:    - +      - +
Rac-GFP
Rac wt
Rac
Total
Erk1/2
MT1-MMP
C
Phospho- 
Erk1/2
*
0
2000
4000
Medium CXCL12 CXCL12
+UO126
In
va
siv
e
ce
lls
Rac wt
Rac CA 
D
Control mAb
Medium CXCL12 CXCL12
+UO126
Anti-MT1-MMP
Ra
c w
t
Ra
c C
A
Ra
c w
t
Ra
c C
A
Ra
c w
t
Ra
c C
A
Medium CXCL12
CXCL12 
+UO126
Pro-MMP2
MMP2
Figure 5. Rac-Erk1/2 signaling controls up-reg-
ulation by CXCL12 of MT1-MMP expression. A:
Cells were incubated for 24 hours with CXCL12
in the absence (control) or presence of LY (20
mol/L) or UO126 (5 mol/L), and tested with
Western blot analyses for MT1-MMP expression.
BLM melanoma cells were transfected with con-
trol or Rac1 siRNA (B), or with GFP-fused wild-
type (wt) or constitutively activated (CA) forms
of Rac (C). Transfectants were subsequently in-
cubated for 24 hours with CXCL12 and subjected
to Western blotting for expression of MT1-MMP,
phospho-Erk1/2, total Erk1/2, and Rac1. D:
Transfectants expressing Rac wt or Rac CA
were subjected to Matrigel invasion assays to-
ward CXCL12, in the absence or presence of
UO126 and control or anti-MT1-MMP mAb
(left). Supernatants from these invasions were
tested by gelatinolytic zymography for MMP-2
activity (right).
7
conditions (not shown). These results indicate that acti-
vation of Rac1-Erk1/2 pathway contributes to up-regula-
tion of MT1-MMP expression and function, as revealed by
MMP-2 activation and enhanced invasion.
Interestingly, when nonstimulated or CXCL12-acti-
vated transfectants were treated with LY for 2.5 hours
previous to the 45-minute period of incubation on Matri-
gel, induction of MT1-MMP cell membrane expression
was largely reduced (Figure 6A). In contrast, no such
inhibition was seen in cells treated with UO126, and
because this inhibitor blocks up-regulation by CXCL12 of
total MT1-MMP expression, surface levels of this metal-
loproteinase on chemokine-incubated cells exposed to
Matrigel were similar to unstimulated counterparts. When
we examined invasiveness, we found that LY and U0126
partially inhibited BLM cell invasion to CXCL12, whereas
the p38 and JNK MAP kinase inhibitors SB203580 and
JNK inhibitor II, did not affect invasion or MT1-MMP re-
distribution to the cell surface (Figure 6, A and B). To-
gether, these results suggest that CXCL12 stimulates
intracellular MT1-MMP accumulation through an Erk1/2
MAP kinase-dependent pathway, and that subsequently
this metalloproteinase redistributes to the cell membrane
after exposure to laminin-containing basement mem-
branes in a PI3-K-dependent manner, a process that
contributes to cell invasion.
Because laminin-1 is a ligand for 1 integrins and 1
integrin-mediated cell adhesion induces PI3-K activa-
tion,29 we tested whether melanoma cell incubation on
Matrigel triggered 1-mediated PI3-K activation, which
might represent a mechanism accounting for MT1-MMP
cell membrane expression. Anti-1 integrin antibodies
blocked melanoma cell attachment to Matrigel, and in-
hibited Matrigel-dependent activation of Akt, a down-
stream PI3-K effector (Figure 6, C and D), suggesting that
this mechanism could indeed mediate the redistribution
of MT1-MMP to the cell membrane.
Discussion
The distinctive homing of tumor cells to organs and tis-
sues during metastasis is contributed by specific attract-
ing molecules, which recruit and promote migration of
circulating tumor cells, and by tumor proteolytic enzymes
that remodel pericellular ECM allowing cell invasion
across tissue barriers to establish new metastatic sites.1
Chemokines and metalloproteinases have been pro-
posed to mediate these processes, leading to tumor cell
dissemination into target organs.2,30 Studies addressing
the individual roles of the chemokine receptor CXCR4
and the metalloproteinase MT1-MMP during in vivo me-
tastasis of melanoma have shown that their overexpres-
sion on the murine B16 melanoma model leads to lung
metastasis.28,31 However, characterization of CXCR4 and
MT1-MMP involvement at different steps of melanoma
cell homing into lungs, whether they are mutually re-
quired during metastasis, as well as whether they es-
tablish mechanistic relationships, has not yet been
investigated. By generating in the same human mela-
noma cell line transfectants either silenced for CXCR4
or MT1-MMP expression, overexpressing these pro-
teins, or having a combination of their silencing and
overexpression, we demonstrate here using xenograft
models that CXCR4 strongly contributes to early migra-
tory steps in melanoma cell homing to lungs. Instead,
MT1-MMP is dispensable for the initial phases, but
together with CXCR4, it promotes subsequent invasive-
ness for efficient lung dissemination, indicating that
these proteins are mutually required during different
steps of melanoma cell metastasis.
In vitro transfectant characterization already revealed
that invasive cell responses involving CXCR4 and MT1-
MMP individually were not sufficient to promote invasion,
but rather their coordinated activities were necessary.
Subsequent in vivo approaches demonstrated that
CXCR4 expression provides melanoma cells with meta-
static advantage over CXCR4 knockdown cells during
early steps of homing into lungs. This conclusion is based
on data from nested PCR experiments that revealed that
CXCR4hi melanoma cells accumulated faster in the lungs
in the first hours after intravenous inoculation than
CXCR4lo counterparts. In addition, adhesion assays
showed that CXCR4hi cells developed stronger attach-
ment under shear stress on endothelial VCAM-1 co-im-
mobilized with CXCL12 compared with CXCR4lo counter-
parts. This in vitro result could mimic the melanoma
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adhesive steps in the lung endothelium, where CXCL12
might be exposed on VCAM-1-rich areas of endothelium,
being capable of up-regulating 41-mediated mela-
noma cell attachment leading to firm arrest. PET-CT anal-
yses together with visual examination of melanoma lung
metastases indicated that rapid and more efficient accu-
mulation of CXCR4hi cells in the lungs led to a posterior
faster organ colonization, causing a notable survival
shortening, as compared with CXCR4lo mice.
In contrast to CXCR4, we found that MT1-MMP was not
needed in early phases of melanoma cell homing into
lungs. However, the activity of this metalloproteinase to-
gether with CXCR4 was required for subsequent dissem-
ination of the tumor because CXCR4hiMT1lo melanoma
cells displayed a significant reduction in their aggressive-
ness in lungs, which was associated with prolonged mice
survival. Additional evidence of mutual requirement be-
tween CXCR4 and MT1-MMP for efficient lung metastasis
was provided by the observation that subcutaneously-
inoculated CXCR4hiMT1lo and CXCR4loMT1hi melanoma
cells displayed a notable decrease in lung colonization
compared with CXCR4hi and MT1hi single counterparts.
The expression of MT1-MMP on the invading tumor front
in melanoma,21 its reported localization on melanoma
invadopodia20 together with our present in vivo data sup-
port an important role for MT1-MMP in melanoma lung
colonization. Although our results strongly indicate that
CXCR4 and MT1-MMP activities are functionally coordi-
nated during different steps of melanoma cell trafficking
into lungs, we cannot exclude that CXCR4hi melanoma
cells might take advantage of CXCL12-dependent
growth properties32,33 to proliferate in the lungs with
higher rates than CXCR4lo counterparts, based on the
shorter doubling times of CXCR4hi cells in the presence
of the chemokine.
Mutual requirement between CXCR4 and MT1-MMP
could take place independently from each other’s activ-
ity, but there might also be molecular cross-talks between
them. Indeed, we previously reported that CXCL12 up-
regulates MT1-MMP expression in melanoma cells, in-
volving Vav-Rho GTPase activation.12,13 Here we have
further characterized this signaling, and thus we show
that Erk1/2 MAP kinase represents a Vav-Rac1-activated
downstream target that is required for stimulation of the
expression and function of MT1-MMP in melanoma cells.
It is well established that the Rac-PAK pathway contrib-
utes to the activation of MEK-Erk1/2 signaling,34,35 and
therefore our data suggest that CXCL12-activated Vav-
Rac1-PAK-Erk1/2 pathway can promote enhancement of
MT1-MMP expression in melanoma cells.
Cell membrane expression levels of MT1-MMP are
generally low, with most of this metalloproteinase residing
intracellularly, likely reflecting a tight cell regulation to
avoid excessive pericellular proteolysis. In agreement
with this expression pattern, MT1-MMP on BLM mela-
noma cells predominantly accumulates intracellularly,
even if its expression is elevated by CXCL12. Interest-
ingly, we have found that when cells come in contact with
components of Matrigel basement membranes, espe-
cially with laminin, a phosphatidylinositol 3-kinase-de-
pendent transient increase in MT1-MMP cell surface ex-
pression is detected, this increase being higher in
CXCL12-incubated CXCR4hi cells. These data indicate
that melanoma cells control their MT1-MMP cell surface
expression after contact with specific ECM proteins. In-
tegrins transmit outside-in signals for PI3-K activation
after interaction with their ECM ligands,33 and thus are
potential candidates to contribute to up-regulation of cell
surface MT1-MMP expression. We show here that 1
integrins mediate melanoma cell attachment to Matrigel
ECM proteins, which causes Akt activation, suggesting
that 1 integrin-dependent PI3-K activation represents a
mechanism likely regulating MT1-MMP cell membrane
expression.
Involvement of PI3-kinase activity in protein trafficking,
both in regulated exocytosis and endocytosis, has been
demonstrated.36–39 In particular, class I and III (hVPS34)
PI3-kinases regulate redistribution of surface proteins to-
gether with key members of the exocytic and endocytic
pathways. Expression of MT1-MMP on the cell surface
has been reported to be regulated, among other pro-
cesses, by internalization,40–42 recycling,43 autocataly-
sis,44 and exocytosis.45,46 At present, it is not known
whether PI3-K-mediated stimulation of exocytosis or inhi-
bition of internalization account for the increase in MT1-
MMP melanoma cell surface expression. Further studies
are needed to better characterize the role of this kinase in
MT1-MMP trafficking to the cell membrane, where it ex-
erts its ECM pericellular remodeling.
Together, these data highlight the cross talk between
CXCR4 and MT1-MMP for efficient melanoma cell inva-
sion. Thus, expression of MT1-MMP is stimulated by
CXCL12 leading to its intracellular accumulation and sub-
sequent redistribution to the cell surface after cell contact
with basement membrane proteins, a mechanism con-
tributing to a greater invasiveness. Accordingly, changes
in cell surface expression of CXCR4 on melanoma should
strongly affect its coordinated activity with MT1-MMP dur-
ing lung metastasis. Expression of CXCR4 in melanoma
and in non-small cell lung cancer can be stimulated by
transforming growth factor-1 and epidermal growth fac-
tor, respectively,12,47 whereas its expression in breast
cancer cells can be increased by HER2 signaling leading
to lung metastasis.48 Additional characterization of the
mechanisms controlling CXCR4 expression will contrib-
ute to improve our knowledge of its metastasis-promoting
properties.
Collectively, the results from the present work dissect
independent and coordinated roles for CXCR4 and MT1-
MMP during the metastasis of melanoma cells into lungs,
establishing molecular cross-talks between these mole-
cules, and suggest that combination therapies targeting
CXCR4 and MT1-MMP should benefit and contribute to
ameliorate the limitations of the current therapies in met-
astatic melanoma.
Acknowledgments
We thank Manuel Moreno, Maria Herrera, and Nohemí
Arellano, from the Centro de Investigaciones Biolo´gicas
Animal Facility, and Isabel Trevin˜o for expert technical
9
assistance; Drs. Goos N.P. van Muijen and Angeles
García-Pardo for cells and reagents; and Dr. Ana C.
Carrera for helpful discussions.
References
1. Chambers AF, Groom AC, MacDonald IC: Dissemination and growth
of cancer cells in metastatic sites. Nat Rev Cancer 2002, 2:563–572
2. Balkwill F: Cancer and the chemokine network. Nat Rev Cancer 2004,
4:540–550
3. Mu¨ller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClana-
han T, Murphy E, Yuan W, Wagner SN, Barrera JL, Mohar A, Veras-
tegui E, Zlotnik A: Involvement of chemokine receptors in breast
cancer metastasis. Nature 2001, 410:50–56
4. Robledo MM, Bartolome RA, Longo N, Rodriguez-Frade JM, Mellado
M, Longo I, van Muijen GN, Sanchez-Mateos P, Teixido J: Expression
of functional chemokine receptors CXCR3 and CXCR4 on human
melanoma cells. J Biol Chem 2001, 276:45098–45105
5. Murakami T, Maki W, Cardones AR, Fang H, Tun Kyi A, Nestle FO,
Hwang ST: Expression of CXC chemokine receptor-4 enhances the
pulmonary metastatic potential of murine B16 melanoma cells. Can-
cer Res 2002, 62:7328–7334
6. Taichman RS, Cooper C, Keller ET, Pienta KJ, Taichman NS, McCauley
LK: Use of the stromal cell-derived factor-1/CXCR4 pathway in pros-
tate cancer metastasis to bone. Cancer Res 2002, 62:1832–1837
7. Smith MC, Luker KE, Garbow JR, Prior JL, Jackson E, Piwnica-Worms
D, Luker GD: CXCR4 regulates growth of both primary and metastatic
breast cancer. Cancer Res 2004, 64:8604–8612
8. Saur D, Seidler B, Schneider G, Algul H, Beck R, Senekowitsch-
Schmidtke R, Schwaiger M, Schmid RM: CXCR4 expression in-
creases liver and lung metastasis in a mouse model of pancreatic
cancer. Gastroenterology 2005, 129:1237–1250
9. Miller AJ, Mihm Jr MC: Melanoma. N Engl J Med 2006, 355:51–65
10. Longo-Imedio MI, Longo N, Trevino I, Lazaro P, Sanchez-Mateos P:
Clinical significance of CXCR3 and CXCR4 expression in primary
melanoma. Int J Cancer 2005, 117:861–865
11. Scala S, Ottaiano A, Ascierto PA, Cavalli M, Simeone E, Giuliano P,
Napolitano M, Franco R, Botti G, Castello G: Expression of CXCR4
predicts poor prognosis in patients with malignant melanoma. Clin
Cancer Res 2005, 11:1835–1841
12. Bartolome´ RA, Galvez BG, Longo N, Baleux F, Van Muijen GN,
Sanchez-Mateos P, Arroyo AG, Teixido J: Stromal cell-derived factor-
1alpha promotes melanoma cell invasion across basement mem-
branes involving stimulation of membrane-type 1 matrix metallopro-
teinase and Rho GTPase activities. Cancer Res 2004, 64:2534–2543
13. Bartolome´ RA, Molina-Ortiz I, Samaniego R, Sanchez-Mateos P,
Bustelo XR, Teixido J: Activation of Vav/Rho GTPase signaling by
CXCL12 controls membrane-type matrix metalloproteinase-depen-
dent melanoma cell invasion. Cancer Res 2006, 66:248–258
14. Seiki M: The cell surface: the stage for matrix metalloproteinase
regulation of migration. Curr Opin Cell Biol 2002, 14:624–632
15. Sternlicht MD, Werb Z: How matrix metalloproteinases regulate cell
behavior. Annu Rev Cell Dev Biol 2001, 17:463–516
16. Sato H, Takino T, Okada Y, Cao J, Shinagawa A, Yamamoto E, Seiki
M: A matrix metalloproteinase expressed on the surface of invasive
tumour cells. Nature 1994, 370:61–65
17. Kurschat P, Zigrino P, Nischt R, Breitkopf K, Steurer P, Klein CE, Krieg
T, Mauch C: Tissue inhibitor of matrix metalloproteinase-2 regulates
matrix metalloproteinase-2 activation by modulation of membrane-
type 1 matrix metalloproteinase activity in high and low invasive
melanoma cell lines. J Biol Chem 1999, 274:21056–21062
18. Sabeh F, Ota I, Holmbeck K, Birkedal-Hansen H, Soloway P, Balbin
M, Lopez-Otin C, Shapiro S, Inada M, Krane S, Allen E, Chung D,
Weiss SJ: Tumor cell traffic through the extracellular matrix is con-
trolled by the membrane-anchored collagenase MT1-MMP. J Cell Biol
2004, 167:769–781
19. Iida J, Wilhelmson KL, Price MA, Wilson CM, Pei D, Furcht LT,
McCarthy JB: Membrane type-1 matrix metalloproteinase promotes
human melanoma invasion and growth. J Invest Dermatol 2004,
122:167–176
20. Nakahara H, Howard L, Thompson EW, Sato H, Seiki M, Yeh Y, Chen
WT: Transmembrane/cytoplasmic domain-mediated membrane type
1-matrix metalloprotease docking to invadopodia is required for cell
invasion. Proc Natl Acad Sci USA 1997, 94:7959–7964
21. Hofmann UB, Westphal JR, Zendman AJ, Becker JC, Ruiter DJ, van
Muijen GN: Expression and activation of matrix metalloproteinase-2
(MMP-2) and its co-localization with membrane-type 1 matrix metal-
loproteinase (MT1-MMP) correlate with melanoma progression.
J Pathol 2000, 191:245–256
22. García-Bernal D, Wright N, Sotillo-Mallo E, Nombela-Arrieta C, Stein
JV, Bustelo XR, Teixido J: Vav1 and Rac control chemokine-promoted
T lymphocyte adhesion mediated by the integrin {alpha}4{beta}1. Mol
Biol Cell 2005, 16:3223–3235
23. Brummelkamp TR, Bernards R, Agami R: A system for stable expres-
sion of short interfering RNAs in mammalian cells. Science 2002,
296:550–553
24. Voorhoeve PM, Agami R: The tumor-suppressive functions of the
human INK4A locus. Cancer Cell 2003, 4:311–319
25. Yang S, Delgado R, King SR, Woffendin C, Barker CS, Yang ZY, Xu L,
Nolan GP, Nabel GJ: Generation of retroviral vector for clinical studies
using transient transfection. Hum Gene Ther 1999, 10:123–132
26. Man˜es S, del Real G, Lacalle RA, Lucas P, Gomez-Mouton C,
Sanchez-Palomino S, Delgado R, Alcami J, Mira E, Martinez AC:
Membrane raft microdomains mediate lateral assemblies required for
HIV-1 infection. EMBO Rep 2000, 1:190–196
27. Albini A, Iwamoto Y, Kleinman HK, Martin GR, Aaronson SA, Kozlowski
JM, McEwan RN: A rapid in vitro assay for quantitating the invasive
potential of tumor cells. Cancer Res 1987, 47:3239–3245
28. Cardones AR, Murakami T, Hwang ST: CXCR4 enhances adhesion of
B16 tumor cells to endothelial cells in vitro and in vivo via beta(1)
integrin. Cancer Res 2003, 63:6751–6757
29. Hynes RO: Integrins: bidirectional, allosteric signaling machines. Cell
2002, 110:673–687
30. Egeblad M, Werb Z: New functions for the matrix metalloproteinases
in cancer progression. Nat Rev Cancer 2002, 2:161–174
31. Rozanov DV, Savinov AY, Golubkov VS, Tomlinson S, Strongin AY:
Interference with the complement system by tumor cell membrane
type-1 matrix metalloproteinase plays a significant role in promoting
metastasis in mice. Cancer Res 2006, 66:6258–6263
32. Kijima T, Maulik G, Ma PC, Tibaldi EV, Turner RE, Rollins B, Sattler M,
Johnson BE, Salgia R: Regulation of cellular proliferation, cytoskeletal
function, and signal transduction through CXCR4 and c-Kit in small
cell lung cancer cells. Cancer Res 2002, 62:6304–6311
33. Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T,
Naeem R, Carey VJ, Richardson AL, Weinberg RA: Stromal fibro-
blasts present in invasive human breast carcinomas promote tumor
growth and angiogenesis through elevated SDF-1/CXCL12 secretion.
Cell 2005, 121:335–348
34. Frost JA, Steen H, Shapiro P, Lewis T, Ahn N, Shaw PE, Cobb MH:
Cross-cascade activation of ERKs and ternary complex factors by
Rho family proteins. EMBO J 1997, 16:6426–6438
35. Eblen ST, Slack JK, Weber MJ, Catling AD: Rac-PAK signaling stim-
ulates extracellular signal-regulated kinase (ERK) activation by reg-
ulating formation of MEK1-ERK complexes. Mol Cell Biol 2002,
22:6023–6033
36. Tengholm A, Meyer T: A PI3-kinase signaling code for insulin-trig-
gered insertion of glucose transporters into the plasma membrane.
Curr Biol 2002, 12:1871–1876
37. Chieregatti E, Meldolesi J: Regulated exocytosis: new organelles for
non-secretory purposes. Nat Rev Mol Cell Biol 2005, 6:181–187
38. Lindmo K, Stenmark H: Regulation of membrane traffic by phospho-
inositide 3-kinases. J Cell Sci 2006, 119:605–614
39. Backer JM: The regulation and function of class III PI3Ks: novel roles
for Vps34. Biochem J 2008, 410:1–17
40. Jiang A, Lehti K, Wang X, Weiss SJ, Keski-Oja J, Pei D: Regulation of
membrane-type matrix metalloproteinase 1 activity by dynamin-me-
diated endocytosis. Proc Natl Acad Sci USA 2001, 98:13693–13698
41. Uekita T, Itoh Y, Yana I, Ohno H, Seiki M: Cytoplasmic tail-dependent
internalization of membrane-type 1 matrix metalloproteinase is
important for its invasion-promoting activity. J Cell Biol 2001, 155:
1345–1356
42. Ga´lvez BG, Matias-Roman S, Yanez-Mo M, Sanchez-Madrid F,
Arroyo AG: ECM regulates MT1-MMP localization with beta1 or al-
phavbeta3 integrins at distinct cell compartments modulating its in-
ternalization and activity on human endothelial cells. J Cell Biol 2002,
159:509–521
10
43. Remacle A, Murphy G, Roghi C: Membrane type I-matrix metallopro-
teinase (MT1-MMP) is internalised by two different pathways and is
recycled to the cell surface. J Cell Sci 2003, 116:3905–3916
44. Stanton H, Gavrilovic J, Atkinson SJ, d’Ortho MP, Yamada KM, Zardi
L, Murphy G: The activation of ProMMP-2 (gelatinase A) by HT1080
fibrosarcoma cells is promoted by culture on a fibronectin substrate
and is concomitant with an increase in processing of MT1-MMP
(MMP-14) to a 45 kDa form. J Cell Sci 1998, 111:2789–2798
45. Zucker S, Hymowitz M, Conner CE, DiYanni EA, Cao J: Rapid traf-
ficking of membrane type 1-matrix metalloproteinase to the cell sur-
face regulates progelatinase a activation. Lab Invest 2002,
82:1673–1684
46. Bravo-Cordero JJ, Marrero-Diaz R, Megias D, Genis L, Garcia-
Grande A, Garcia MA, Arroyo AG, Montoya MC: MT1-MMP proinva-
sive activity is regulated by a novel Rab8-dependent exocytic path-
way. EMBO J 2007, 26:1499–1510
47. Phillips RJ, Mestas J, Gharaee-Kermani M, Burdick MD, Sica A,
Belperio JA, Keane MP, Strieter RM: Epidermal growth factor and
hypoxia-induced expression of CXC chemokine receptor 4 on non-
small cell lung cancer cells is regulated by the phosphatidylinositol
3-kinase/PTEN/AKT/mammalian target of rapamycin signaling path-
way and activation of hypoxia inducible factor-1alpha. J Biol Chem
2005, 280:22473–22481
48. Li YM, Pan Y, Wei Y, Cheng X, Zhou BP, Tan M, Zhou X, Xia W,
Hortobagyi GN, Yu D, Hung MC: Upregulation of CXCR4 is essential
for HER2-mediated tumor metastasis. Cancer Cell 2004, 6:459–469
11
